Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab + erlotinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pertuzumab + erlotinib is an investigational combination therapy comprising the HER2-targeted monoclonal antibody pertuzumab (Perjeta) and the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva). The combination was developed by Roche and Genentech to achieve enhanced antitumor activity through the dual blockade of the human epidermal growth factor receptor (HER) family signaling. It has been primarily studied in patients with relapsed non-small cell lung cancer (NSCLC) and refractory pancreatic adenocarcinoma. However, clinical trials in NSCLC (such as NCT00855894) were halted early due to poor tolerability, with a high incidence of grade 3 or greater adverse events, including pneumatosis intestinalis, which has limited its further clinical development in that indication.
- Brand names
- Perjeta + Tarceva
- Other names
- pertuzumab and erlotinib
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pertuzumab + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab + erlotinib.